NYMC Faculty Publications

Overall Survival of Children and Adolescents with Mature B Cell Non-Hodgkin Lymphoma Who Had Refractory or Relapsed Disease During or After Treatment with FAB/LMB 96: A Report from the FAB/LMB 96 Study Group

DOI

10.1111/bjh.15491

Journal Title

British Journal of Haematology

First Page

859

Last Page

869

Document Type

Article

Publication Date

9-1-2018

Department

Pediatrics

Abstract

We determined the risk factors associated with poor survival in children and adolescents with de novo mature B cell non-Hodgkin lymphoma (B-NHL) who had refractory or relapsed disease during or after the French-American-British mature lymphoma B (FAB/LMB) 96 multi-agent chemotherapy. Among the 1 111 registered on study, 104 patients (9.4%) had refractory disease or disease relapse after first complete remission. Among these 104 patients, 28 (27%) patients had refractory disease and 76 (73%) had relapsed disease. The estimated 1- and 2-year overall survival (OS) (95% confidence interval) was 31.5% (23.3-41.0%) and 22.3% (15.3-31.4%), respectively. Prognostic analysis of OS using a Cox multivariate model showed that factors independently associated with OS included lactate dehydrogenase >/=2 upper normal limit [hazard ratio (HR) = 2.86 (1.57-5.2), P = 0.0006]; time to failure (>6 months) [HR = 0.59 (0.36-0.97), P = 0.038]; and failure in bone marrow [HR = 2.78 (1.65-4.68), P = 0.0001]. New therapeutic strategies are required to significantly reduce refractory disease and disease relapse in patients with newly diagnosed mature B-NHL and, more importantly, there is a critical need to develop novel retrieval approaches in patients with chemotherapy-resistant disease.

Link to Full Text

Share

COinS